Abstract

The role of wireless capsule endoscopy (WCE) in small bowel Crohn’s disease (SBCD) has been studied in many clinical trials and has been shown to be superior to other modalities (eg, barium radiography, colonoscopy with ileoscopy, computed tomography enterography, push enteroscopy) for diagnosing and evaluating non-stricturing SBCD. There have been concerns about the risk of capsule retention in SBCD because of small bowel strictures, with reported capsule retention rates in patients with known SBCD as high as 13% (range 4–13). Our purpose is to demonstrate the safety of WCE in patients with known or suspected SBCD in our community based, private practice that specializes in inflammatory bowel disease (IBD). We performed a retrospective chart review of patients with confirmed SBCD who had undergone WCE between 2001 and 2013. Patients with documented bowel obstruction; radiographic or endoscopic evidence of strictures <1 cm in diameter; history of bowel obstruction, stenotic surgical hookups, or intestinal scarring were excluded from undergoing WCE per facility protocol. All patients had either a computed tomographic enterography, magnetic resonance enterography or small bowel follow-through in addition to careful prescreening history and physical exam to evaluate for WCE exclusion criteria prior to any capsule swallow. Ninety eight patients with confirmed SBCD underwent WCE and were included in the study; 43% (n = 42) males, 57% (n = 56) females with a mean age of 42, and mean disease duration of 7.49 years (range <1–46). Thirty five patients (36%) had CD for ≤1 year in duration at the time of WCE, and the majority had mild-to-moderate CD. Of the 98 patients, 25 patients had serial capsule studies for reassessment during the 12 year study period, with a total of 75 WCE studies done on this population. Of the 94 patients, and 148 separate studies only 1 capsule was retained (0.7%) in this 12 year period. This retained capsule was easily removed by endoscopy from a duodenal stricture. WCE can be safely performed in SBCD patients, as evidenced by our single center, community IBD practice performing 148 WCE procedures on 98 patients revealing only one single retention event. We believe that careful selection of appropriate patients allows for the safe use of WCE technology in patients with SBCD. By having a single expert physician in inflammatory bowel disease evaluate and prescreen each patient with a carefully taken medical history, physical exam, and use of radiography prior to WCE, the risk of capsule retention in this population is minimized.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.